(Q28286240)

English

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

scientific article

In more languages

Statements

scholarly article

0 references

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial (English)

0 references

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

randomized experiment

1 reference

based on heuristic

inferred from title

Richard M Bergenstal

1

object named as

Richard M Bergenstal

0 references

author name string

Carol Wysham

2

0 references

Leigh Macconell

3

0 references

Jaret Malloy

4

0 references

Brandon Walsh

5

0 references

Ping Yan

6

0 references

Ken Wilhelm

7

0 references

Jim Malone

8

0 references

Lisa E Porter

9

0 references

language of work or name

0 references

publication date

7 August 2010

0 references

0 references

376

0 references

431-9

0 references

9739

0 references

randomized experiment

0 references

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Does comparative effectiveness have a comparative edge?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative-effectiveness research--implications of the Federal Coordinating Council's report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New, but not improved? Incorporating comparative-effectiveness information into FDA labeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing weight-related quality of life in obese persons with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)60590-9

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28286240&oldid=1505043821"